Logo

Cenix Expands AstraZeneca Agreement

Jun 15, 2009

NEW YORK (GenomeWeb News) – Cenix Bioscience said today that it has expanded an oncology drug research agreement with AstraZeneca to include RNAi-based studies for respiratory and inflammation-related conditions.

Under the new agreement, which expands upon a deal announced in March, Cenix will complete at least three projects using its RNAi gene silencing technology as well as image analysis using Definiens’ Cellenger platform.

These studies will involve multi-pass genome-scale screens using assays developed by AstraZeneca in high-throughput RNAi studies in 384-well and 1,536-well formats.

Financial terms of the expanded agreement were not released.

Filed under

Gene Editing, Gene Silencing, & CRISPR
Disease Research
Cancer
Cenix BioScience
inflammation
RNAi
gene silencing
AstraZeneca
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.